Alnylam Pharmaceuticals (ALNY) Cash & Equivalents (2009 - 2026)

Alnylam Pharmaceuticals' Cash & Equivalents history runs 18 years deep, the most recent figure standing at $1.7 billion for Q1 2026.

• Quarterly Cash & Equivalents rose 67.78% year-over-year to $1.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 billion (up 67.78% YoY) and the FY2025 annual result came in at $1.7 billion, up 71.09% from the prior year.
• Cash & Equivalents was $1.7 billion for Q1 2026 at Alnylam Pharmaceuticals, up from $1.7 billion in the prior quarter.
• Across five years, Cash & Equivalents topped out at $1.7 billion in Q1 2026 and bottomed at $534.1 million in Q1 2022.
• A 5-year average of $996.3 million and a median of $968.7 million in 2024 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents retreated 22.82% — and 2025, when it jumped 71.09%.
• Alnylam Pharmaceuticals' Cash & Equivalents stood at $868.6 million in 2022, then slipped by 6.43% to $812.7 million in 2023, then increased by 19.19% to $968.7 million in 2024, then soared by 71.09% to $1.7 billion in 2025, then climbed by 3.23% to $1.7 billion in 2026.
• Business Quant data shows ALNY's Cash & Equivalents at $1.7 billion in Q1 2026, $1.7 billion in Q4 2025, and $1.5 billion in Q3 2025.